Q-omics provides the consensus-scored F2RL3 profile across patient tissues and cancer cell-line models. F2RL3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, F2RL3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, F2RL3 RNA expression shows 16,300 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where F2RL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for F2RL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes F2RL3 survival associations across molecular data types. F2RL3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible F2RL3 RNA expression–survival associations across cancer types. High F2RL3 expression shows unfavorable associations in UVM, KIRP, ACC and COAD, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for F2RL3 RNA expression.
This table summarizes F2RL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for F2RL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. F2RL3 shows lower tumor expression in LUSC, LUAD and KIRP and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher F2RL3 RNA expression in tumor versus normal tissue (log2 FC = +2.370, t-test p < 0.001).
This table shows molecular features associated with F2RL3 in patient tissues and cancer cell lines. In patient samples, F2RL3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, F2RL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
